Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Access

Set Alert for Market Access

Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?

Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.

Biosimilars Market Access Pricing Strategies
Advertisement

Market Access

Set Alert for Market Access

Latest From Market Access

Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A

Shire's cash-strapped partner Xenetic, whose technology enabled the long-acting Factor VIII, said on May 22 that SHP656 could not achieve once-weekly dosing in a Phase I/II clinical trial. The market for such a product may be limited anyway given current competition and payer preferences.

Research & Development Commercial

Lilly-Lupin Bolster India Alliance But Cialis Faces Crowded Market

Eli Lilly and Lupin are building on their alliance in India, with Lupin introducing Lilly’s Cialis (tadalafil) – a teeming market awaits the product, however.

Commercial Generic Drugs

Novartis's Entresto Voyage: Hindsight Is 20/20

What caused Novartis's innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto's journey and what this experience shows about the changing face of pharma's customers.

Cardiovascular Market Access

PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches

After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.

Cardiovascular Market Access

Regeneron Hypes New Eczema Drug Dupixent In 1Q

Analysts have significantly upped their 2017 sales forecasts for Regeneron and Sanofi's recently launched eczema drug Dupixent on the back of a strong first few weeks on the market and positive vibes from Regeneron – which held a spotlight firmly on its new therapy during its May 4 first quarter earnings call.

Commercial Sales & Earnings

US Branded Drug Invoice Price Increases Moderate In 2016

Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.

Pricing Debate Pricing Strategies
See All
UsernamePublicRestriction

Register